GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cidara Therapeutics
Cidara, a biotech focused on fighting fungal infections, is driven by the progress of its clinical programs. Its price trajectory depends on research results and partnerships, as hospitals are in dire need of new antifungal drugs.
Share prices of companies in the market segment - Pharma virus
Cidara, a biotech focused on fighting fungal infections, is driven by the progress of its clinical programs. We classify it as a Pharma Virus company, and the chart below shows the dynamics of the entire segment, where the need for new antifungal drugs is very high.
Broad Market Index - GURU.Markets
Cidara Therapeutics is a biotech company developing drugs for the treatment and prevention of serious fungal and viral infections. It is a component of the GURU.Markets index. The chart below shows the market. See how Cidara shares compare to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
CDTX - Daily change in the company's share price Cidara Therapeutics
Cidara Therapeutics shares exhibit extreme volatility, as measured by change_co. This reflects sensitivity to the results of clinical trials of its antifungal drugs. This metric is a key component of the formulas on System.GURU.Markets for biotech risk analysis.
Daily change in the price of a set of shares in a market segment - Pharma virus
Cidara Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with CDTX's performance, which depends on the clinical trial results of its antifungal drugs, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Cidara is a biopharmaceutical company developing drugs to treat fungal infections. This segment of biotech is highly volatile. The chart below reflects average fluctuations in this industry, providing context for assessing the risks and potential of Cidara shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cidara Therapeutics
Cidara is a biotech company specializing in fighting viral diseases. Its shares are driven by news about new drug developments. This dynamic, specific to the pharmaceutical industry, creates fluctuations that contribute to overall volatility.
Annual dynamics of market capitalization of the market segment - Pharma virus
Cidara Therapeutics is a clinical-stage biotech developing anti-infective drugs. Its stock performance is driven entirely by clinical trial results and partnerships, not revenue. The chart below shows how the market views the company's scientific potential and risks compared to other companies.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cidara Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cidara Therapeutics
Cidara, a biotech company developing drugs to treat and prevent fungal infections, is a key player in the market. Monthly fluctuations on the chart reflect news about clinical trials, regulatory decisions, and commercial partnerships, which are key for companies at this stage.
Monthly dynamics of market capitalization of the market segment - Pharma virus
Cidara Therapeutics is a biotech company developing a new generation of antifungal drugs and universal preventatives for viral infections such as influenza. The graph below shows the overall dynamics in the infectious disease sector, where the need for new, effective medications remains high.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cidara Therapeutics is a clinical-stage biotech developing anti-infective drugs. Its stock moves not with the market, but with news about clinical trials. The success or failure of a single trial can trigger explosive growth or collapse, which is typical of venture capital investments in biotech.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cidara Therapeutics
Shares of Cidara Therapeutics, a biotech company fighting fungal infections, reflect the demand for new antimicrobial agents on a weekly basis. Price movements are a response to clinical trial data and the growing problem of pathogen resistance to existing drugs.
Weekly dynamics of market capitalization of the market segment - Pharma virus
Biotech fighting infectious diseases is a sector where weekly performance depends on clinical data and partnerships. Antibiotic resistance is a common challenge for everyone. This chart illustrates this backdrop, against which Cidara Therapeutics is seeking new solutions.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cidara Therapeutics develops drugs to treat fungal infections. This is an important, yet niche, area of pharmaceuticals. This chart will help us understand: are Cidara shares stuck in a world of clinical trials and regulatory news, or are the overall market conditions and risk appetite in biotech actually influencing their stock price?
Market capitalization of the company, segment and market as a whole
CDTX - Market capitalization of the company Cidara Therapeutics
Cidara's market capitalization reflects the story of a biotech company focused on combating serious fungal and viral infections. Its volatile price chart reflects progress in developing the Cloudbreak platform for creating immune-boosting drugs. Its dynamics reflect the market's assessment of both its own clinical programs and partnerships with major pharmaceutical companies.
CDTX - Share of the company's market capitalization Cidara Therapeutics within the market segment - Pharma virus
Cidara Therapeutics is a biotech company developing new antifungal drugs and a platform for creating long-acting immunotherapeutics. Its market share currently reflects its potential. Its market capitalization is a bet on the success of its developments in the fight against dangerous infections.
Market capitalization of the market segment - Pharma virus
Cidara Therapeutics is a biotech company developing new antifungal drugs and immunotherapies. The chart below shows the overall market capitalization of this sector. Its dynamics reflect the ongoing need for new methods to combat infections, especially in the face of growing resistance to existing drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cidara Therapeutics develops new antifungal drugs and a platform for creating long-acting immunotherapeutics. Its market capitalization reflects the need for new methods to combat infections. The chart below shows the weighting of biotech companies in this field.
Book value capitalization of the company, segment and market as a whole
CDTX - Book value capitalization of the company Cidara Therapeutics
Cidara Therapeutics' balance sheet represents its capital invested in the development and research of new antifungal drugs and immunotherapy platforms. This provides a tangible, scientific foundation for fighting dangerous infections. How has this biotech asset changed during clinical trials? The chart below shows its dynamics.
CDTX - Share of the company's book capitalization Cidara Therapeutics within the market segment - Pharma virus
Cidara Therapeutics develops long-acting antifungal drugs, which requires research laboratories. The chart shows the share of these science-intensive tangible assets in the sector, reflecting the physical foundation upon which the company fights dangerous infections.
Market segment balance sheet capitalization - Pharma virus
Anti-infective drug development, as the BCap_Seg chart for biotech shows, is not as capital-intensive as manufacturing. Cidara Therapeutics operates in this environment, where its assets are a scientific platform and patents, not factories. It's a business where intellectual capital trumps physical capital.
Book value of all companies included in the broad market index - GURU.Markets
Cidara Therapeutics' assets are not production lines, but cutting-edge laboratories and the Cloudbreak technology platform for immunotherapy development. The book value reflects the capital invested in the scientific infrastructure aimed at creating drugs capable of combating dangerous viral infections.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cidara Therapeutics
Cidara Therapeutics develops antifungal and antiviral drugs. Like many biotechs, its balance sheet is primarily funded by research. Its market capitalization reflects the company's hopes for drug approval. The MvsBCap chart will reflect each step in clinical trials, showing how news impacts its scientific potential.
Market to book capitalization ratio in a market segment - Pharma virus
Cidara Therapeutics is a biotech company developing new anti-infective drugs. Its value depends almost entirely on the success of clinical trials and the potential of its Cloudbreak® platform. The chart reflects investors' high appreciation for this scientific potential.
Market to book capitalization ratio for the market as a whole
Cidara Therapeutics fights serious fungal and viral infections. Like many development-stage biotech companies, its market value reflects the potential of its scientific platforms rather than its tangible assets. Investors are betting on the future success of clinical trials, as this chart illustrates.
Debts of the company, segment and market as a whole
CDTX - Company debts Cidara Therapeutics
Cidara Therapeutics, a biotech company developing anti-infective drugs, relies entirely on external funding to conduct clinical trials. Until its products are approved, the company generates no revenue. This chart illustrates how the company manages its limited resources during the long and risky process of drug discovery.
Market segment debts - Pharma virus
Cidara Therapeutics develops new anti-infective drugs and immunotherapies. For a biotech company in the clinical development stage, access to capital is vital. Its financing structure, including debt instruments, reflects its strategy for bringing its developments to market. The chart provides insight into this aspect.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cidara Therapeutics
Cidara Therapeutics develops long-acting anti-infective drugs. The chart shows how the biotech company finances its R&D activities. Having debt without stable revenue is a significant risk for a company, but it also reflects the creditors' confidence in its scientific platform. Its size indicates a stake in the future success of its drugs.
Market segment debt to market segment book capitalization - Pharma virus
Cidara Therapeutics is a biotech company developing antiviral and antifungal drugs. This chart, for the pharmaceutical industry as a whole, illustrates how the sector attracts capital for long and risky clinical trials. It helps assess the company's financial position in the context of the high costs typical of biotech.
Debt to book value of all companies in the market
Cidara Therapeutics is a biotech company. Its funding depends on investor confidence in its future drugs. This chart reflects the overall risk appetite in the economy. For a company without revenue, it helps understand how its debt or equity financing model compares to the overall market.
P/E of the company, segment and market as a whole
P/E - Cidara Therapeutics
For Cidara Therapeutics, a biotech company fighting fungal infections, this chart reflects investor expectations for its scientific platform. The values on it reflect the market's faith in the potential of its drugs and their ability to offer new solutions for treating serious diseases, particularly in immunocompromised patients.
P/E of the market segment - Pharma virus
This chart shows the average P/E for the biotech sector in which Cidara Therapeutics operates. The industry's high average valuation reflects hopes for scientific breakthroughs. The chart illustrates this general backdrop against which Cidara's niche development in antifungal drugs is valued.
P/E of the market as a whole
Cidara Therapeutics develops new, long-acting anti-infective drugs aimed at treating and preventing serious fungal and viral infections. This is an important and complex area of medicine. This chart, reflecting overall risk appetite, helps us understand whether investors are willing to fund Cidara's lengthy and expensive drug development process in the hopes of future success.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cidara Therapeutics
Cidara Therapeutics is a biotech company developing long-acting anti-infective drugs. The chart reflects investor expectations for future revenue, which depend on the success of clinical trials and partnerships with major pharmaceutical companies. This is a bet on innovation in the fight against resistant infections.
%20P%2FE%20Cidara%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cidara-Therapeutics&v=1772612526694 "Chart of the company's future (projected) P/E Cidara Therapeutics")
Future (projected) P/E of the market segment - Pharma virus
Cidara Therapeutics develops new long-acting anti-infective drugs, including antifungals. The company aims to address the growing problem of drug resistance. The chart reflects future profit expectations in the biotech sector, helping to understand how highly the market perceives Cidara's chances of success in this important niche.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-virus&v=1772612526715 "Future (projected) P/E graph of the market segment - Pharma virus")
Future (projected) P/E of the market as a whole
Cidara Therapeutics is a biotech company developing new long-acting anti-infective drugs. Its value depends on the success of clinical trials and future demand for new antibiotics and antifungals. This chart of overall risk appetite shows how willing investors are to invest in pharmaceutical innovation.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772612526720 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cidara Therapeutics
Cidara Therapeutics is a biotechnology company developing new anti-infective drugs and immunotherapies. Being in clinical development, its financial metrics primarily reflect research expenses. This chart shows the investment in the development of new drugs to combat antibiotic-resistant infections.
Profit of companies in the market segment - Pharma virus
Cidara Therapeutics is a biotechnology company developing new anti-infective drugs, including antifungal agents and comprehensive viral prophylaxis. This chart reflects the broader picture in the pharmaceutical sector, where combating drug-resistant pathogens is one of the most pressing healthcare challenges.
Overall market profit
Cidara Therapeutics is a biotech company developing new anti-infective drugs and immunotherapies. Its success depends entirely on clinical trial results and regulatory approval. This process is insulated from short-term economic fluctuations, which can be seen in this chart. The company's value is determined by scientific potential, not market conditions.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cidara Therapeutics
Cidara Therapeutics is a biotechnology company developing novel anti-infective drugs and immunotherapies. Its future profitability depends on the success of clinical trials and partnerships with major pharmaceutical companies. This chart reflects analysts' speculative expectations regarding the commercial potential of Cidara's research and development work.
%20profit%20of%20the%20company%20Cidara%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cidara-Therapeutics&v=1772612526757 "Graph of future (projected) profit of the company Cidara Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma virus
Cidara Therapeutics is a biotechnology company developing novel anti-infective drugs and immunotherapies. Its Cloudbreak platform aims to create universal treatments against influenza and other viruses. This chart shows revenue projections for the pharmaceutical sector, allowing one to assess the potential of Cidara's innovative approaches in the fight against infectious diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-virus&v=1772612526759 "Graph of future (predicted) profits of companies in a market segment - Pharma virus")
Future (predicted) profit of the market as a whole
Cidara Therapeutics is a biotech company focused on developing long-acting anti-infective therapeutics. Its future depends on successful clinical trials and partnerships. This economic outlook affects the availability of venture capital and the willingness of large pharmaceutical companies to invest in biotech.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772612526763 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cidara Therapeutics
Cidara Therapeutics develops long-acting anti-infective drugs. During clinical development, revenue may be minimal and come from partnerships. This graph reflects investors' confidence in the company's scientific platform and its ability to bring new treatments to market against serious infections.
P/S market segment - Pharma virus
Cidara Therapeutics is a biotech company developing long-acting therapies for the prevention and treatment of serious fungal and viral infections. Their approach has the potential to revolutionize treatment for vulnerable patient groups. This chart shows the average revenue estimate for the sector, providing insight into how the market values Cidara's innovative platform.
P/S of the market as a whole
Cidara Therapeutics is a biotech company developing new anti-infective drugs and immunotherapies. The company is addressing the problem of growing antibiotic resistance. This chart highlights that the valuation of such early-stage companies is based less on revenue than on investor confidence in the scientific approach and potential of future drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cidara Therapeutics
Cidara Therapeutics is a biotech company developing long-acting anti-infective treatments. For a development-stage company, future revenue estimates are hypothetical but important. They reflect investors' confidence in the potential of its Cloudbreak platform and the future commercial success of its drugs in the fight against drug-resistant infections, a significant challenge.
%20P%2FS%20Cidara%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cidara-Therapeutics&v=1772612526797 "The graph of the company's future (projected) P/S Cidara Therapeutics")
Future (projected) P/S of the market segment - Pharma virus
Cidara Therapeutics is a biotech company developing new anti-infective drugs and immunotherapies. This chart shows how investors view the company's future revenues relative to the pharmaceutical sector. It demonstrates the market's confidence in its Cloudbreak platform for creating conjugates capable of delivering antiviral agents directly to cells, and the potential of its developments.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20virus&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-virus&v=1772612526817 "Future (projected) P/S market segment graph - Pharma virus")
Future (projected) P/S of the market as a whole
Cidara Therapeutics develops long-acting antifungal medications. The company operates in a highly specialized healthcare niche. In the overall revenue growth picture illustrated by this chart, Cidara represents an innovative biotech company solving specific medical problems.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772612526832 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cidara Therapeutics
This chart shows the revenue of Cidara Therapeutics, a biotech company developing novel antifungal and antiviral drugs. Revenue is generated from sales of its first commercial product, as well as from partnerships, such as with Janssen. The growth in this indicator reflects successful commercialization and progress in clinical development.
Sales of companies in the market segment - Pharma virus
Cidara Therapeutics develops long-acting anti-infective drugs. Its primary revenue currently comes from collaborations with large pharmaceutical companies such as Janssen. Its future sales structure will depend on the success of its lead candidate, which demonstrates the biotech startup's growth model.
Overall market sales
Cidara Therapeutics is a biotech company developing new, long-acting anti-infective drugs. Its value is determined by the potential of its scientific developments and the success of clinical trials. This general economics curve has virtually no impact on a company solving fundamental problems in medicine, where demand is driven by treatment needs, not financial cycles.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cidara Therapeutics
Cidara Therapeutics is a biotechnology company developing novel anti-infective drugs and immunotherapies. Its future revenue depends on the success of clinical trials, partnerships, and the commercialization of its developments. This chart reflects analyst forecasts for potential revenue from licensing fees and future drug sales.
%20sales%20of%20the%20company%20Cidara%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cidara-Therapeutics&v=1772612526859 "Schedule of future (projected) sales of the company Cidara Therapeutics")
Future (projected) sales of companies in the market segment - Pharma virus
Cidara Therapeutics is developing new long-acting anti-infective drugs, including antifungals. This chart shows sales forecasts for the biotech sector. Is the need for new antibiotics and antifungals growing due to resistance? This reflects the overall relevance of the company's developments for the entire industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-virus&v=1772612526862 "Schedule of future (projected) sales of companies in the market segment - Pharma virus")
Future (projected) sales of the market as a whole
Cidara Therapeutics is a biotech company developing long-acting anti-infective drugs. Its prospects depend on the results of clinical trials, FDA approval, and the competitive environment in the pharmaceutical industry. General economic cycles, which can be tracked on this chart, have little impact on the demand for effective infection treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772612526865 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cidara Therapeutics
Cidara Therapeutics is a biotechnology company developing long-acting medications for the treatment and prevention of serious fungal and viral infections. This chart reflects its financial position at the clinical development stage. Profitability is a future goal, and current indicators reflect the level of investment in the development of innovative anti-infective agents.
Market segment marginality - Pharma virus
Cidara Therapeutics is a biotechnology company developing novel anti-infective drugs and immunotherapies. Currently in clinical trials, the company is actively investing in R&D. This chart reflects its current financial position, with future profitability entirely dependent on the success of its scientific developments, regulatory approvals, and partnerships.
Market marginality as a whole
Cidara Therapeutics is a biotech company developing drugs to treat serious fungal and viral infections. Its future depends on successful clinical trials and raising funding. This total return chart reflects the investment climate. In a healthy economy, investors are more inclined to invest in risky but promising biotech projects.
Employees in the company, segment and market as a whole
Number of employees in the company Cidara Therapeutics
Cidara Therapeutics is a biotech company developing long-acting anti-infective drugs. Its small staff consists of scientists and researchers. This graph reflects the stage of development: team growth may be associated with the advancement of a key drug into late-stage clinical trials, which requires expansion of the clinical and regulatory departments.
Share of the company's employees Cidara Therapeutics within the market segment - Pharma virus
Cidara Therapeutics is a biotech company developing new long-acting anti-infective drugs. Its core asset is its team of research scientists working in laboratories to create new molecules. This graph shows the company's market share in a narrow biotech niche, and its dynamics reflect progress in research and development.
Number of employees in the market segment - Pharma virus
Cidara Therapeutics develops long-acting anti-infective drugs, including antifungals. This chart shows employment trends in the pharmaceutical sector specializing in the treatment of viral and fungal diseases. Growth in this area underscores the need for new methods to combat resistant infections, which is Cidara's mission.
Number of employees in the market as a whole
Cidara Therapeutics is a biotech company developing new antifungal drugs and immunotherapies. The growth of its research team, compared to the overall employment in this chart, is an indicator of progress in the fight against resistant infections. Hiring here reflects not the economic cycle, but the success of clinical trials and the need for new drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cidara Therapeutics (CDTX)
Cidara Therapeutics is a biotech company developing anti-infective drugs. This chart shows how the market values their scientific platform. The entire value can be captured in a single promising development. The per-employee market cap can be extremely high, reflecting investors' expectations for future success.
%20of%20the%20company%20Cidara%20Therapeutics%20(CDTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cidara-Therapeutics-CDTX&v=1772612527033 "Chart of market capitalization per employee (in thousands of dollars) of the company Cidara Therapeutics (CDTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma virus
Cidara Therapeutics (CDTX) is a biotech company developing drugs to treat and prevent serious fungal and viral infections using its Cloudbreak platform. This chart shows the average market cap per employee in the sector. It helps assess how the market values their R&D platform and partnerships (e.g., with J&J) per scientist.
%20by%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-virus&v=1772612527069 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma virus")
Market capitalization per employee (in thousands of dollars) for the overall market
Cidara Therapeutics is a biotech company developing drugs to treat fungal infections and new approaches to oncology. At the clinical development stage, its value is determined by its scientific potential. The chart shows a high valuation per employee, as investors factor in future revenues from the successful launch of innovative drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772612527083 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cidara Therapeutics (CDTX)
Cidara is a biotech company developing new treatments for fungal and viral infections. The company is at the intersection of R&D and commercialization. This chart shows how successfully the company monetizes its developments (e.g., through partnerships) and whether these profits cover the costs of the research team working on new drugs.
%20Chart%20Cidara%20Therapeutics%20(CDTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cidara-Therapeutics-CDTX&v=1772612527104 "Company Profit Per Employee (in thousands of dollars) Chart Cidara Therapeutics (CDTX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma virus
Cidara (CDTX) is an R&D biotech (antifungal). This chart shows the benchmark for "Pharma" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-virus&v=1772612527113 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma virus")
Profit per employee (in thousands of dollars) for the market as a whole
Cidara Therapeutics is a biotech company specializing in the treatment of fungal and viral infections. It is an R&D company that recently received approval (Rezzayo) and transferred it to a partner. This chart shows the transition phase: burning capital on R&D and receiving the first royalties, which should cover the costs of employing scientists.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772612527131 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cidara Therapeutics (CDTX)
Cidara Therapeutics is a biotech company developing anti-infective drugs. At the clinical trial stage, this metric may be zero. However, it represents potential: if successful, a single approved drug could generate enormous revenue, dramatically increasing this metric and reflecting the value of their research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cidara-Therapeutics-CDTX&v=1772612527145 "Sales chart per company employee Cidara Therapeutics (CDTX)")
Sales per employee in the market segment - Pharma virus
Cidara Therapeutics is a biotech company developing new antifungal drugs and the "Cloudbreak" platform for creating long-acting therapies. It's an R&D-focused business. This chart shows the average revenue in the sector. For CDTX, this is an indicator: how much revenue per employee is their scientific platform already generating (possibly through partnerships)?
Sales per employee for the market as a whole
Cidara Therapeutics is a biotech company developing treatments for serious fungal and viral infections. While in the R&D stage, the company may have little or no revenue. This indicator will become important after the product launch, demonstrating how effectively a small team can commercialize the drug.
Short shares by company, segment and market as a whole
Shares shorted by company Cidara Therapeutics (CDTX)
Cidara (CDTX) is a biotech company developing antifungal and antiviral drugs. This chart shows the volume of short positions. As with many clinical-stage companies, high short positions signal that investors are betting against the success of the company's developments in clinical trials or are doubtful of the commercial potential of its drugs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cidara-Therapeutics-CDTX&v=1772612527226 "Short Shares Chart for the Company Cidara Therapeutics (CDTX)")
Shares shorted by market segment - Pharma virus
Cidara Therapeutics (CDTX) is a biotech company developing new anti-infective drugs and immunotherapies. This chart aggregates short positions across the entire biotech sector. It reflects investor skepticism regarding the risks of clinical trials and the challenges of commercializing new antibiotics.
Shares shorted by the overall market
Cidara (CDTX) is a clinical-stage biotech (antifungal). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives CDTX of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cidara Therapeutics (CDTX)
Cidara Therapeutics (CDTX) is a biotech company specializing in the development of long-acting anti-infective drugs, particularly antifungals. Their success depends on R&D. This chart is an oscillator that indicates hype. It can signal "overbought" (above 70) on positive trial data or "oversold" (below 30) on news of delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cidara-Therapeutics-CDTX&v=1772612527245 "RSI 14 indicator chart for the company's stock Cidara Therapeutics (CDTX)")
RSI 14 Market Segment - Pharma virus
Cidara Therapeutics (CDTX) is a biotech company developing a new generation of long-acting antifungal drugs. The RSI_14_Seg for their biotech segment shows the overall sentiment. The chart helps us understand: is CDTX's volatility a reaction to their clinical trials, or is the entire sector overheated (or oversold)?
RSI 14 for the overall market
Cidara Therapeutics (CDTX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CDTX (Cidara Therapeutics)
Cidara Therapeutics is a biotech company developing drugs to combat serious fungal and viral infections. Its unique Cloudbreak platform "engages" the immune system to fight disease. This chart shows the average analyst forecast. Their price targets are based on the success of partnerships (such as with J&J) and the progress of their clinical programs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CDTX-Cidara-Therapeutics&v=1772612527301 "A chart showing analyst consensus forecasts for the expected stock price. CDTX (Cidara Therapeutics)")
The difference between the consensus estimate and the actual stock price CDTX (Cidara Therapeutics)
Cidara Therapeutics is a biotech company developing long-acting treatments. Their main hope is the Cloudbreak platform, which aims to create a single shot per year to prevent influenza. This chart reflects analysts' speculative expectations for their preclinical and clinical programs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CDTX-Cidara-Therapeutics&v=1772612527322 "A chart showing the difference between the consensus forecast and the actual stock price. CDTX (Cidara Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma virus
Cidara Therapeutics is a biotech company developing a new class of immunotherapy (Cloudbreak) for the treatment of serious fungal and viral infections. This chart shows analysts' overall expectations for the viral pharmaceutical sector. It reflects whether experts believe in the commercial potential of new antifungal drugs.
Analysts' consensus forecast for the overall market share price
Cidara Therapeutics is a biotech company developing long-acting antifungal drugs and an immunotherapy platform for viruses (influenza). This chart shows overall market sentiment. For Cidara, as an R&D company, it's important to understand how overall risk appetite (analyst sentiment) influences funding for their clinical trials. (348)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cidara Therapeutics
Cidara (CDTX) is a biotech company focused on treating serious infections (antifungal drugs). Their second pillar is the Cloudbreak platform for developing long-acting therapies. This chart represents their R&D bet. It reflects the commercial launch of their first drug and the market's confidence in the potential of their technology platform to create new, successful treatments.
AKIMA Market Segment Index - Pharma virus
Cidara Therapeutics (CDTX) is a clinical-stage biotech and a pioneer in anti-infective therapeutics. The company is developing the Cloudbreak platform, which delivers antiviral agents (Dimerics). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does CDTX's innovative R&D platform (Cloudbreak) differentiate it from the average pharma company?
The AKIM Index for the overall market
Cidara Therapeutics is a biotech company developing immunotherapy for the treatment and prevention of serious infectious diseases (influenza, fungus). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative scientific story compares to the overall economic trends affecting the healthcare sector.
